Muna Therapeutics vs 80 Acres Farms

Side-by-side comparison of AI visibility scores, market position, and capabilities

Muna Therapeutics

EmergingBioTech

Neuroscience

Muna Therapeutics raised $75M in 2024 targeting microglial biology in Alzheimer's disease, using iPSC-derived microglia models to identify novel drug targets that modulate brain immune function.

About

Muna Therapeutics focuses on microglial biology — the specialized immune cells of the brain — as the key to developing disease-modifying Alzheimer's therapies beyond amyloid targeting. The company uses induced pluripotent stem cell (iPSC)-derived microglia as disease models to identify and validate novel drug targets implicated by Alzheimer's genetics (TREM2, PLCG2, BIN1, APOE). This platform enables the company to study microglial dysfunction at scale and run drug screens against human-relevant cellular models.

Full profile

80 Acres Farms

ChallengerAgTech

Indoor Vertical Farming

Raised $115M (Feb 2026) led by General Atlantic. Post-merger with Soli Organic creates largest indoor farm in North America. ~$200M combined first-year revenues.

About

80 Acres Farms is a commercial-scale indoor vertical farming company that, following its merger with Soli Organic, operates the largest indoor farming network in North America. The company raised $115 million in February 2026 led by General Atlantic, with projected first-year combined revenues approaching $200 million — making it one of the few vertical farming companies to achieve genuine commercial scale after years of industry attrition that eliminated several high-profile competitors.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.